Galcanezumab
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research[1].
Product Specifications
CAS Number
1578199-75-3
Product Name Alternative
LY 2951742
UNSPSC
12352203
Target
CGRP Receptor
Type
Inhibitory Antibodies
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/galcanezumab.html
Purity
98.00
Solubility
H2O
Smiles
[Galcanezumab]
Molecular Weight
(145.5 kDa)
References & Citations
[1]Yvette N Lamb. Galcanezumab: First Global Approval. Drugs. 2018 Nov;78 (16) :1769-1775.|[2]Hashikawa-Hobara N, et al., Lack of alpha CGRP exacerbates the development of atherosclerosis in ApoE-knockout mice. Sci Rep. 2024 Aug 8;14 (1) :18377.|[3]Benschop RJ, et al., Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthritis Cartilage. 2014 Apr;22 (4) :578-85.
Shipping Conditions
Blue Ice
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
